Search
Dexamethasone Treatment Options in Michigan
A collection of 270 research studies where Dexamethasone is the interventional treatment. These studies are located in the Michigan, United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
61 - 72 of 270
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
Completed
This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
02/24/2025
Locations: Infusion Associates Site Number : 1001, Grand Rapids, Michigan
Conditions: Fabry's Disease
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Active Not Recruiting
This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Chemotherapy drugs, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than o... Read More
Gender:
ALL
Ages:
Between 1 year and 31 years
Trial Updated:
02/20/2025
Locations: C S Mott Children's Hospital, Ann Arbor, Michigan +8 locations
Conditions: B Acute Lymphoblastic Leukemia, Central Nervous System Leukemia, Testicular Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
Opioid-Free Pain Protocol After Shoulder Arthroplasty
Active Not Recruiting
This randomized, single blinded, clinical trial aims to investigate the efficacy of a multimodal pain control regimen for shoulder arthroplasty. Patients who receive a multimodal pain control regimen alone (study group) will be compared to patients who receive a multimodal pain control regimen plus a standard prescription of an opioid containing medication (comparison group). The primary outcome is average daily Numerical Rating Scale (NRS) pain score in the first 10 days after surgery. We hypot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Shoulder Arthropathy, Shoulder Pain
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Completed
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: University of Michigan Health System, Ann Arbor, Michigan +1 locations
Conditions: Relapsed Refractory Multiple Myeloma
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Terminated
This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Multiple Myeloma, Relapsed Refractory Multiple Myeloma
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Completed
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract.
The primary purpose of this study is to determine the recommended dose of CAEL-101 to facilitate progression of further clinical trials and evaluate safety and tolerability o... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/12/2025
Locations: Research Site, Detroit, Michigan
Conditions: AL Amyloidosis
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Active Not Recruiting
This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is no... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
02/01/2025
Locations: C S Mott Children's Hospital, Ann Arbor, Michigan +8 locations
Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Completed
The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/31/2025
Locations: Not set, Detroit, Michigan
Conditions: Multiple Myeloma
Isatuximab As Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Active Not Recruiting
This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis). Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: AL Amyloidosis
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
Terminated
The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin and paclitaxel) every 3 weeks.
Gender:
FEMALE
Ages:
Between 18 years and 89 years
Trial Updated:
01/30/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Gynecologic Cancer
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
Active Not Recruiting
This is a Phase 3 randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma, eligible to subjects who completed autologous stem cell transplant for symptomatic myeloma who are considered for lenalidomide maintenance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Wayne State University - Karmanos Cacner Institute, Detroit, Michigan
Conditions: Multiple Myeloma
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
Terminated
This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Saint Joseph Mercy Hospital, Ann Arbor, Michigan +58 locations
Conditions: Malignant Neoplasm
61 - 72 of 270